HC Wainwright Forecasts Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Krystal Biotech in a research note issued to investors on Wednesday, February 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of $1.56 per share for the quarter. HC Wainwright has a “Buy” rating and a $221.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.74 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.24 EPS, FY2025 earnings at $6.97 EPS, FY2026 earnings at $6.23 EPS, FY2027 earnings at $8.49 EPS and FY2028 earnings at $8.78 EPS.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the firm earned $0.30 earnings per share. The company’s revenue was up 116.4% compared to the same quarter last year.

KRYS has been the topic of a number of other reports. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and an average target price of $210.00.

Krystal Biotech Stock Performance

Shares of KRYS opened at $181.10 on Monday. Krystal Biotech has a 52-week low of $125.85 and a 52-week high of $219.34. The business’s 50 day moving average price is $158.24 and its two-hundred day moving average price is $175.31. The firm has a market cap of $5.22 billion, a PE ratio of 60.57 and a beta of 0.84.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 14.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently bought and sold shares of KRYS. Norges Bank bought a new stake in Krystal Biotech during the fourth quarter worth $34,391,000. Soleus Capital Management L.P. grew its holdings in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after buying an additional 141,400 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after buying an additional 122,407 shares in the last quarter. State Street Corp grew its holdings in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after buying an additional 119,936 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Krystal Biotech during the fourth quarter worth $15,989,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).